Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYHX1901 in Moderate to Severe Plaque Psoriasis
CTR20230629Phase 2Completed
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in psoriasis comparing SYHX1901 active treatment with SYHX1901 placebo (2 arms). Primary endpoint: PASI75 response at week 12. Started Mar 2023; status: completed.
02
Drugs
SYHX-1901
03
Conditions
psoriasis
Beyond the preview
Go deeper on CTR20230629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230629.